Abstract: Carotenoid dietary intake, especially within fruits/vegetables and their plasma levels have been associated in many epidemiological studies with a reduced risk of several chronic diseases, including type-2 diabetes, cardiovascular diseases, several types of cancer, and agerelated macular degeneration. However, intervention trials with isolated carotenoids (as supplements) have fallen short of fulfi lling the hopes that were placed in these lipophilic pigments, often producing no positive or even adverse effects, such as increased lung cancer rate or total mortality. More recent studies have suggested that certain metabolites, and not necessarily the native compounds may be (the most) biologically active ones, such as certain apocarotenals (originating following enzymatic cleavage) and other more polar compounds, acting as more suitable electrophiles to react with transcription factors such as nuclear factor kappa-B (NF-KB) and nuclear factor (erythroid-derived 2)-like 2 (Nrf2). In addition, it appears that questions of dosing are likewise crucial, as may be interactions of non-provitamin A carotenoids and their derivatives with retinoic acid receptors (RAR) or retinoid X receptors (RXR). Furthermore, our picture on carotenoid metabolism may be incomplete, as our knowledge on e. g. the interaction with the microbiota is virtually nil. In this position article, it is aimed to highlight some of the discrepancies that appear to trouble carotenoid-related research, and point out some of the existing gaps in our knowledge.
Epidemiological studies and carotenoids
Apart from representing essential precursors for vitamin A [1; 2; 3] , several large and prospective epidemiological studies have shown a positive correlation between the dietary intake of carotenoids and reduced risk of developing several chronic diseases. For example, in a meta-analysis with over 135,000 participants, Hamer and Chida [4] have shown that the consumption of total carotenoids was associated with a reduced risk (almost 30 %) of type 2 diabetes (T2D). Similarly, in a study with over 70,000 female participants, dietary intake of α-and β-carotene was significantly associated with a reduced risk (25 % and 20 %, respectively) of coronary artery disease, when comparing quintiles of highest vs. lowest intake [5] . A comparable result was found by Buijsse et al. [6] in a meta-analysis of prospective cohort studies (with ca. 4500 participants), showing that plasma β-carotene in elderly men was associated with an overall reduced total mortality (of almost 30 %). Though the mechanisms of action remained unclear at the time, it was speculated that carotenoid antioxidant capacity (involving quenching of free radicals such as of lipid peroxides) was likely to be associated with the observed eff ects [7] .
Intervention trials with carotenoid supplements -hard endpoints
These positive fi ndings and related antioxidant activity seen in many in vitro trials [8] sparked a number of largescale supplementation trials, especially with β-carotene. Most recognized for their adverse eff ects on smokers, both the ATBC [9] and the CARET trial [10] , in which β-carotene was (co-) administered at high daily doses of 20 mg with 50 mg α-tocopherol and 30 mg with 25,000 IU vitamin A, respectively, for several years, had to be discontinued due to increased lung-cancer mortality. Similar fi ndings were encountered in a meta-analysis by Bjelakovic et al. (also including healthy subjects), suggesting that β-carotene supplements resulted in enhanced mortality when given alone or together with other antioxidants [11] . Supplementation trials fi nding a positive (or at least, no negative) eff ect do also exist, such as the Linxian trial [12] , though it may be speculated that eff ects can be, at least in part, explained by a reduced status of certain micronutrients in these populations, and that supplementation rather ameliorated these defi ciencies.
Short-term dietary intervention trials -surrogate markers
Several intervention trials with whole foods, notably with tomato products rich in carotenoids (lycopene, β-carotene) have been conducted, which generally suggested some positive health eff ects, as measured by surrogate markers, such as those related to infl ammation, e. g. interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin 1-beta (IL-1β), tumor necrosis factor alpha (TNF-α), C-reactive protein (CRP), or oxidative stress, e. g. improving superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase (CAT), or heme-oxygenase 1 (HO-1) [13; 14] ). The same appears to be true to some extent for non-healthy subjects, in which the intervention with supplements, such as with lycopene or lutein, has shown some benefi ts, as measured e. g. by improved serum amyloid A (a marker of infl ammation), and IL-6 [14; 15] .
These endpoints were chosen, as mechanistic, i. e. in vitro/cellular trials, had suggested that not the direct antioxidant eff ects (e. g. free radical quenching) may be responsible for the proposed health eff ects, but also (and perhaps especially) eff ects on gene expressions, such as via altering cellular transcription factors linked to infl ammation and oxidative stress, as reviewed by Kaulmann and Bohn [16] . It appears that certain carotenoids and their derivatives can bind to cysteine residues of nuclear factor kappa-B (NF-KB) or nuclear factor (erythroid-derived 2)-like 2 (Nrf2). This can prevent the degradation of the inhibitor of NF-KB and thus the liberation of free NFkB (and subsequent translocation to the nucleus which up-regulates pro-infl ammatory gene-expression, fi gure 1); and for Nrf2 fostering dissociation from the kelch-like ECH-associated protein 1 (keap-1) repressor, with Nrf2 then translocating to the nucleus, up-regulating expression of anti-oxidant enzymes [17; 18] .
Are we looking at the right compounds?
How to explain the conundrum of discrepancies between epidemiological fi ndings and intervention trials? Are we targeting the wrong molecules? Are other compounds, such as dietary fi bre, anti-oxidant vitamins (C/E), or other bioactive secondary plant compounds (e. g. phytosterols, glucosinates etc.), and not carotenoids, responsible for the observed health eff ects?
This extreme position may also fall short of the reality. There are several aspects to consider prior to "ripping off " Higher carotenoid concentrations (depending on carotenoid type, organism, bioavailability etc.) may increase the risk, at least intermittently, of reactive oxygen species (ROS) production, activating nuclear factor (erythroid derived 2)-like 2 (Nrf2) translocation and expression of anti-oxidant enzymes. Likewise, nuclear factor-kappa B (NF-κB) translocation may be inhibited, limiting pro-infl ammatory responses. Lower concentrations, possibly covering the lower/physiological range, may even reduce Nrf2 translocation, effects for NF-κB are less clear. Certain derivatives of β-carotene, but also of lycopene, can alter retinoic acid receptor (RAR) and retinoid x receptor (RXR) activity, effecting apoptosis, with lower concentrations of retinoic acid/other derivatives possibly favouring cell proliferation [22] . Higher concentrations of native carotenoids may reduce the proportion of carotenoid derivatives (non-fi lled arrows, possibly involving β-carotene oxygenases 1/2 (BCO1/2). High concentrations of native compounds have further been suggested to trigger cytochrome P450 enzyme (CYP) activation, producing pro-carcinogenic compounds [38] . *effects for higher/lower doses (on NF-κB and Nrf2) shown in vitro and in vivo especially for astaxanthin, β-carotene, lutein, lycopene [16] . +: Data for β-carotene and derivatives. $: Data for β-carotene derivatives and indications for apo-15-lycopenoids. CAT: catalase; GPx: glutathione peroxidase; HO-1: heme-oxygenase 1; IL-1β: interleukin-1-beta; IL-6: interleukin-6; NO: nitric oxide; SOD: superoxide-dismutase; TNF-α: tumor necrosis factor alpha.
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Are we overlooking something?
Other pathways, which so far have been mostly overlooked, may also play a role, which likewise may involve carotenoid metabolites. Caris-Veyrat et al. [27] have suggested that lycopene metabolites such as apo-15-lycopenoids show vitamin A -like behaviour, as they may activate retinoid X receptor (RXR) and retinoic acid receptor (RAR) [28; 29; 30] . Also eff ects together with other bioactive compounds, such as with docosahexaenoic acid (DHA) and ATRA, on RAR/ RXR mediated apoptosis have been reported [31] , highlighting potential additive/synergistic interactions with other micronutrients. Also in this respect, more is known for other phytochemicals such as for polyphenols [32] , but little on carotenoids.
When highlighting potential dose eff ects, it is also important to stress out inter-individual diff erences in doseresponses, possibly related to genetic diff erences such as single nucleotide polymorphisms (SNPs), altering carotenoid metabolism and bioavailability [33; 34] . Possibly also epigenetic diff erences do play a role, however, no information on this is available.
Finally, several aspects of potential carotenoid metabolism have never been investigated. A good example is the human colon and its microbiota. As only 10-40 % of carotenoids are absorbed (presumably, in the small intestine), the majority of carotenoids can reach the large intestine. In vitro studies have further suggested that carotenoids are not completely recovered, only 10 % [35] -50 % [36] . Obviously, they are fermented -but into what? From polyphenols, we know that these may be converted into numerous metabolites, following ring fi ssion, deglycosylation, hydrolysis, deglucuronidation, and demethylation [37] . However, nothing is known regarding carotenoids. It is not impossible that bioactive, more polar degradation products are formed. Though admittedly this is speculation, it is remarkable that nothing on colonic metabolism is known.
Conclusions and Perspectives
Our current view on potential bioactive properties on carotenoids appears to be incomplete. Missing aspects include the following: 1. Which metabolites and breakdown products are formed in the human body? 2. Does the colon and especially microbiota play any role in carotenoid metabolism? 3. Are the (more polar) metabolites the (more) bioactive molecules -rather than the native compounds? If so, which exactly?
carotenoids the status of any health benefi ts. It rather appears that our understanding of carotenoid bioavailability and bioactivity, especially regarding the active compounds and possibly dose-related aspects, is incomplete: It can be hypothesized that carotenoids, administered at high doses (supplements), may override the body's metabolism capacity, increasing the ratio of native compounds to metabolites, resulting in more pro-oxidant and pro-infl ammatory conditions. Indeed, several studies have suggested that β-carotene oxygenase 1/2 (BCO1/2) cleavage metabolites, due to their enhanced electrophilic properties (with improved binding ability to cysteine residues of NF-KB and Nrf2), and higher solubility in the cytosol, are better alterators of these pathways, resulting in anti-infl ammatory eff ects, and stimulating the body's own antioxidant system [17] . Highest bioactivity regarding these pathways was associated with apocarotenals with 12 C-atoms, and having a methyl-group 3 C-atoms distant from the terminal aldehyde function [17] . In addition, several studies in vitro [18] and even in vivo in rats [19] have shown that polar carotenoid breakdown products of lycopene and lutein (following UV-Vis irradiation), respectively, are more bioactive with respect to anti-infl ammatory/antioxidant targets (related to transcription factors), supporting this hypothesis.
Higher, i. e. supra-physiological doses on the other hand (1-10 μM in cellular trials, or doses exceeding the daily intake of ca. 10-20 mg [20] ), have in part been related to pro-oxidative eff ects in some, though not all studies, as reviewed earlier [16] . For example, in several cellular trials, concentrations of > 1 μM of all-trans retinoic acid (ATRA), a potential metabolite of β-carotene, have been associated with pro-oxidative eff ects [21] , as opposed to lower, nutritionally plausible concentrations (< 1 μM) [16] . Earlier results in smoke-exposed ferrets [22] have likewise suggested arbitrary eff ects at low vs. high concentrations of β-carotene (0.4 vs. 2.4 mg/kg bw., equal to 6 and 30 mg/kg bw. for humans), in line with the ATBC/CARET trial, resulting in lower retinoic acid concentrations and reduced retinoic acid receptor (RAR)-β expression, hampering apoptosis but increasing cytochrome P450 activation, possibly resulting in the formation of harmful metabolites.
Such concentrations (> 30 mg/kg bw.), taken for several weeks, are likely to considerably increase the typical β-carotene plasma concentration from 0.3-1.0 μM to 3-5 μM or higher [23; 24; 25] , which thus may not be desirable. Also higher doses of lycopene (3.3 mg/kg bw. in rats) have shown arbitrary eff ects, interestingly especially when ethanol reduced BCO2 activity [26] , also pointing out to the importance of the balance between metabolites and native carotenoids. These merely constitute some of the most pressing questions that should be addressed in order to lift the veil of the unresolved bioactivity that carotenoids may exert, and should be addressed prior to future large-scale supplemental experiments. It can be hoped for that improved in vitro (e. g. 3-D cell culture) and in vivo (e. g. knock-out) models, higher availability of (metabolite) standards, and improved analytical capabilities will contribute to solve some of these persistent puzzles.
